ClinicalTrials.gg
WithdrawnNCT01801878Updated Oct 23, 2020

Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts

An interventional study of Adipose SVF cell and Normal saline in Breast Neoplasms and Skin Abnormalities, sponsored by Seoul National University Hospital. Withdrawn at 1 site in Korea, Republic of. Open to female participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Supportive care

Why this study was withdrawn
Difficulty in recruiting research subjects
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
Female
01

Study summary

The aim of this study is to evaluate the skin quality of using adipose-drived stromal vascular fraction (SVF) cell taken by automatic centrifuge for adipose-drived cell isolation system into irradiated breasts.

Read the detailed description

10 participants who taken conservative mastectomy will be enrolled

  1. Process

    • adipose tissue is obtained from the subject's thigh or abdomen
    • adipose-drived stromal vascular fraction(SVF)cell isolation using automatic centrifuge system
    • adipose-drived stromal vascular fraction(SVF)cell graft into the irradiated breast.
  2. Duration of study

    • entire duration: approximate 30weeks
    • Follow-up period: 12 weeks
    • Enrollment period: 12 weeks
  3. Study design - Randomized, prospective, pilot study
02

Conditions studied

  • Breast Neoplasms
  • Skin Abnormalities

Keywords

  • breast cancer
  • loss of elasticity in irradiated breast skin
  • Other Reconstructive Surgery
03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female aged between 40 and 60
  • Subjects who diagnosed breast ductal carcinoma in situ of surgical staging T1aN0, negative resection margin of below 2mm in histopathologic examination
  • Subjects who have a relapse-free interval of more than one year after breast-conserving surgery for breast cancer and radiation therapy
  • Subjects who understand the study contents and sign the

Exclusion criteria

Exclusion Criteria:

  • Subjects who have radiodermatitis
  • Subjects who planned breast reconstruction with autogenous tissue (ex.Transverse Rectus Abdominis Muscle flap)
  • Subjects who have a history of smoking within 3months recently
  • Subjects who participated in other clinical trial within 30 days recently
  • Pregnant or lactating subjects
  • Subjects who have a active infectious disease
  • Subjects who are not eligible for this study at the discretion of the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Adipose SVF cell

    adipose SVF cell transfer to the half of irradiated breast

    Biological: Adipose SVF cell

  • Active comparator
    Normal saline

    Normal saline inject to the half of irradiated breast

    Biological: Normal saline

Interventions

  • BiologicalAdipose SVF cell

    adipose SVF cell transfer to the half of irradiated breast

  • BiologicalNormal saline

    Normal saline inject to the half of irradiated breast

06

What researchers measure

Primary outcomes

  1. The change in the breast skin thickness of the pre and post SVF graft from baseline at 12week after procedure

    The efficacy is assessed by breast skin thickness measured by radiologist using breast ultrasonography

    Time frame: change in the breast skin thickness from baseline at 12 week

07

Study locations

1 site
  • Seoul National Univ. Bundang Hospital
    Seongnam-si, Bundang,Gyeonggi-do 463-707, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01801878
Responsible party
Sponsor
First posted
Mar 1, 2013
Start date
Dec 1, 2020 (estimated)
Primary completion
Oct 30, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Oct 23, 2020

Study contacts

Chanyeong Heo, Ph.D
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion